The positive earnings surprise and strategic acquisition by Harmony Biosciences are significant factors that investors typically view favorably, leading to increased demand for HRMY shares. The better-than-expected earnings indicate operational efficiency and profitability, while the acquisition of Epygenix Therapeutics could open new growth avenues, enhancing investor optimism about the company's future prospects.